Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study published in ...

The kidney health benefits of SGLT2 inhibitors extend to patient subgroups with chronic kidney disease (CKD) in combo with other conditions.

"This was the largest nationwide population-based longitudinal cohort study to investigate the association between the use of ...

bDepartment of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Aging Research, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein ...

New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a newer class of drugs used to manage diabetes, have recently been linked ...

Recurrent stroke risk was lower among patients with type 2 diabetes who used SGLT2 inhibitors within 3 months of ischemic stroke.

In ACTIV-4a, 215 (75%) of 285 patients in the SGLT2 inhibitor (dapagliflozin, empagliflozin or canagliflozin) plus standard-of-care group did not require respiratory or cardiovascular organ support ...

The FINEARTS-HF late-breaking data were forefront at the 2024 European Society of Cardiology Congress in London.

Ozempic, a GLP-1 receptor drug originally produced to treat diabetes, has become the next star product of the multi-million ...